Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
- 1 January 2002
- journal article
- review article
- Published by Springer Science and Business Media LLC in Molecular Psychiatry
- Vol. 7 (S1), S71-S80
- https://doi.org/10.1038/sj.mp.4001021
Abstract
Molecular Psychiatry publishes work aimed at elucidating biological mechanisms underlying psychiatric disorders and their treatmentKeywords
This publication has 104 references indexed in Scilit:
- Attenuation of Ketamine Effects by Nimodipine Pretreatment in Recovering Ethanol Dependent Men Psychopharmacologic Implications of the Interaction of NMDA and L-Type Calcium Channel AntagonistsNeuropsychopharmacology, 2001
- Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in RatsScience, 1998
- Subgenual prefrontal cortex abnormalities in mood disordersNature, 1997
- Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studiesNeuroscience & Biobehavioral Reviews, 1997
- Low brain GABA level is associated with poor seizure controlAnnals of Neurology, 1996
- The effect of gabapentin on brain gamma‐aminobutyric acid in patients with epilepsyAnnals of Neurology, 1996
- Ketamine activates psychosis and alters limbic blood flow in schizophreniaNeuroReport, 1995
- Amantadine-induced aggressiveness.BMJ, 1972
- AMANTADINE IN DEPRESSIONThe Lancet, 1971
- AMANTADINE DOSAGE IN TREATMENT OF PARKINSON'S DISEASEThe Lancet, 1970